chemotherapy. The patient received allogeneic SCT from an HLA-2 antigen mismatched father without CR after receiving a conditioning regimen consisting of total body irradiation (TBI), topotecan and melphalan in March 2008. Acute graft-versushost disease (GVHD) of the skin (stage 2) was observed, but resolved with corticosteroids. Immunosuppressive treatment was stopped on day 37. WT1 mRNA level was higher than normal. 4 Case 2 was a 13-year-old girl who developed tumor of the upper eyelid and showed pancytopenia in February 2008. BM aspiration revealed AML with AML/MTG8 translocation on fluorescence in situ hybridization analysis. She received chemotherapy according to the JPLSG (Japan Pediatric Leukemia/ Lymphoma Study Group) AML-05 protocol. She achieved CR after the second course of chemotherapy. Because a high WT1 mRNA level (3500 copies/mg RNA in BM) was observed, she received HLA-matched unrelated umbilical cord blood transplantation after a conditioning regimen consisting of TBI and cyclophosphamide in October 2008. Acute cutaneous GVHD (stage 3), observed on day 19 post-transplant, resolved after prednisolone administration. WT1 and AML/MTG mRNA levels remained abnormally high (Table 1) . Case 3 was a 1-year-old boy without Down syndrome who presented high fever and thrombocytopenia in June 2008. A diagnosis of acute megakaryoblastic leukemia was made following BM aspiration. He was successfully treated with the JPLSG AML-05 protocol but relapsed 3 months after the end of treatment. He achieved morphological CR with topotecan-based combination chemotherapy, but WT1 mRNA level remained high (180 000 copies/mg RNA in BM). He received allogeneic bone marrow transplantation from an HLA-identical unrelated donor in July 2009. The conditioning regimen consisted of busulfan and melphalan. He developed no GVHD and immunosuppressive treatment was stopped on day 35 post-transplant. WT1 mRNA levels increased to as high as 2300 copies/mg RNA in BM on day 34 post-transplant.
WT1 vaccinations were started at 1-week interval in these three cases on day 41-173 post-SCT. WT1 mRNA levels in BM were as high as 1500-2600 copies/mg RNA before WT1 vaccination. After vaccination, WT1 mRNA levels decreased to 150-470 copies/mg RNA on day þ 180 in all cases, whereas WT1-specific CTL frequencies increased from 0-0.14% to Letters to the Editor 0.5-2.1% in peripheral blood (PB) and from 0% to 0.19-0.29% in BM (Tables 1 and 2 ). WT1-specific CTLs were detected in BM of all cases after vaccination, but in none before vaccination. In Case 2, who had the chimeric marker AML-MTG8 as MRD, the decrease of WT1 mRNA correlated with the decrease of AML-MTG8 after vaccination. Cases 1 and 2 have subsequently received WT1 peptide vaccination once monthly and are still in CR for 33.5 and 40.3 months from SCT (Table 2 ). In Case 3, disease recurred again on day þ 201 after 23 doses of vaccination, whereas WT1-specific CTL frequency increased further to 0.85% (Table 2) . Surface HLA expression on leukemic cells disappeared (data not shown), which implies occurrence of immunological escape of the leukemic cells. T-cells have been phenotypically classified into four differentiation stages: the naïve (N), the central memory (CM), the effector memory (EM) and the terminal differentiated effector (E) stage. 5 The frequency of WT1-specific CTLs and differentiation subpopulation analysis in our cases are shown in Table 2 . In healthy subjects WT1-specific CTL frequencies in PB are usually o0.1%.
4,6
The proportion of E or EM subset in the CTLs in PB of Cases 1 and 3 after vaccination was higher than that of healthy donors. In healthy donors, 80.0±8.4% (mean±s.d.) of the CTLs were reported to be N-type cells. 7, 8 The origin of WT1-specific CTLs was donor type. There were no systemic vaccination-related adverse effects or exacerbation of GVHD.
WT1 has recently been recognized as having a high potential for immunotherapy by the National Cancer Institute Pilot Project. 9 However, the trials for childhood cancer are currently limited to our previous study where we found that the effect of WT1 peptide vaccination might be insufficient in the presence of gross residual disease. 10 Taking this into consideration, we conducted this study that was designed to prevent recurrence at MRD after SCT.
One ALL patient (Case 1) had chemo-resistant relapse and received SCT without remission. In the other two AML patients, one patient had primary induction failure and the other had AML M7 without Down syndrome, which has a poor prognosis. Considering the disease history of each patient before vaccination, all three met the criteria for high risk of relapse.
Monitoring of MRD by WT1 mRNA measurement is applicable to almost all leukemias including pediatric leukemias. Ogawa et al. 11 reported that WT1 measurement is highly useful for the prediction and management of relapse following allogeneic SCT; the probability of relapse was significantly increased according to the increase in WT1 mRNA levels. In our cases, WT1 transcripts in BM were 410 3 copies/mg/RNA before allogeneic SCT, which is above the normal upper limit, 4,12 and therefore, predicted the patients' poor prognosis.
WT1 transcripts in BM were elevated in all cases before WT1 peptide vaccination. However, levels decreased after vaccination to o10 3 copies/mg RNA, indicating its effectiveness. Case 2 had the chimeric marker AML-MTG8 as MRD. Tobal et al. 13 have reported that patients in durable remission had levels of AML/MTG8 transcripts o1 Â 10 3 molecules/mg RNA in BM, whereas those having X2.27 Â 10 3 molecules/mg RNA were at high risk of relapse. AML/MTG8 transcript levels in Case 2 were higher than this threshold. WT1 peptide vaccination induced reduction of transcript levels of AML/MTG8, as well as WT1, followed by a long-term CR, which indicates strong evidence for the vaccine's therapeutic potential.
WT1-specific CTLs in PB were detected and increased after vaccination in all cases (Table 2 ). Case 3 subsequently had recurrence during WT1 peptide vaccination despite increased frequencies of WT1-specific CTLs in PB. HLA expression disappeared on the surface of leukemic cells, suggesting a possibility that the cells had escaped from immunoreaction by WT1 peptide. Combined usage of interferons, which upregulate HLA expression on leukemic cells, may enhance the sensitivity of the cells to WT1-specific CTLs. We also evaluated WT1-specific CTL subpopulations. In Cases 1 and 2, the frequency of CM and EM cells increased. The enhanced ability of CM and EM T-cells to confer antitumor effects has been reported to be correlated with their greater proliferative capacity. 14 WT1-specific CTLs originated from donor cells that are considered to be activated and differentiated by stimulation with tumor cell-derived WT1 protein. Rezvani et al. 15 have reported that the loss of these CTLs is associated with relapse. On the contrary, we found that the emergence of WT1-specific CTLs was associated with a decrease in WT1 mRNA, suggesting a WT1-driven GVL effect.
In conclusion, we report the first three cases in a phase II trial of WT1 peptide immunotherapy after SCT for pediatric patients. Our results highlight the potential of WT1 vaccination to boost the GVL effect. Larger studies are needed on the application of WT1 vaccination to prevent recurrence after pediatric SCT.
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Letters to the Editor
High expression of BAALC in cytogenetically normal-acute myeloid leukemia (AML) patients is associated with primary resistant disease, shorter relapse-free, disease-free and overall survival. [1] [2] [3] [4] However, there is no published data evaluating the role of BAALC in the hematopoietic system. BAALC is located on human chromosome 8q22.3 and is highly conserved in mammals. High BAALC expression levels were first identified in a study of AML patients with trisomy 8 as a sole abnormality, 5 and was shown to correlate highly with MN1 expression, 6, 7 a potent oncogene in leukemogenesis. 8 Several isoforms of BAALC have been described with isoform 2 (also known as 1-6-8) being the most abundant in the brain and in AML samples. 5 Using retroviral gene transfer, bone marrow (BM) transplantation and expression analysis of BAALC and MN1 in cytogenetically normal AML patients, we evaluated the role of BAALC in hematopoiesis. Details of materials and methods can be found in the Supplementary information. In total, 140 newly diagnosed adult AML patients with cytogenetically normal AML were evaluated by real-time RT-PCR for BAALC and compared with MN1 transcript expression.
2,3 BAALC expression was found to correlate highly with MN1 expression (R ¼ 0.71, Pearson's correlation, Figure 1a) .
This finding stimulated us to further investigate whether BAALC was upregulated as a consequence of MN1 upregulation or vice versa. Retroviral overexpression of human full-length MN1 in a murine model system induces rapid-onset AML. 8, 9 We used murine BM cell lines immortalized by retroviral expression of Hoxa9 or NUP98HOXD13, and co-transduced these cells with full-length MN1 or a control vector as described before. 10 Baalc expression was not increased but rather decreased in MN1-expressing NUP98HOXD13 cells as compared with control transduced NUP98HOXD13 cells (Figure 1b) . Baalc expression decreased in BM cells that were freshly transduced with MN1 or Hoxa9 compared with control transduced BM cells
